New PhD thesis uses QCM sensor from Attana to investigate protein interactions on inflammatory cells
In a recent PhD thesis published from Uppsala University Attana technology was used to study blood protein binding to inflammatory cells.
Attana technology has been applied by Dr. Tor Persson Skare in Professor Lena Claesson-Welsh’s group at Uppsala University in their study of Histidine-rich protein (HRG) and Stanniocalcin 2 (STC2) interactions and their effects on inflammatory cells. Both HRG and STC2 are found in blood and have been shown to have an impact on inflammatory processes. In the PhD thesis, a manuscript with the title “Histidine-rich glycoprotein and stanniocalcin-2 high affinity interactions with inflammatory cells” used the QCM sensor from Attana extensively to study the interaction between HRG and STC2.
This work provides further insights into mechanisms underlying both macrophage function and differentiation, and the role of the proteins HRG and STC2 in these processes. Macrophages play a pivotal role in the tumor microenvironment where they induce either pro-tumoral or anti-tumoral responses dependent on influences from the environment, for example exposure to HRG and STC2. Key questions asked were whether HRG and STC2 interactions are specific and whether they bind to the same cell surface receptor. Kinetic analysis using Attana QCM technology revealed a stable and conformation-dependent interaction of the two proteins with nanomolar affinity. QCM technology was also used to study protein-cell surface interactions, which showed that HRG and STC2 bind to different molecular species on the surface of inflammatory cells.
HRG and STC2 conformation dependent binding and binding to inflammatory cells
Top row: Schematic of experimental setup used to study the HRG-STC2 interaction on Attana COP-1 chip.
Bottom row: Schematic illustration of immobilized inflammatory cells (U937 model), either immature (left) or differentiated (right) on Attana COP-1 chip. The biomolecular interaction was monitored in real time, label-free on both live cells and fixed cells using the Attana Cell™ 200 instrument.
The full publication can be found here.
To view all publications enabled by Attana, follow this link.
For more information, please contact:
Teodor Aastrup, CEO
teodor.aastrup@attana.com
+46 (0)8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
About Attana
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com
Tags:
